*RUNX* family transcription factors are essential regulators of diverse developmental processes, including cell proliferation, differentiation, apoptosis, and cell lineage specification ([@ref4]). *RUNX* genes were independently identified as the fly segmentation gene Runt, a leukemia associated gene, and the subunit of a virus enhancer binding protein. Mammals possess three *RUNX* genes, *RUNX1*, *RUNX2*, and *RUNX3*, which form a heterodimeric complex in the presence of a b subunit, CBFb. Although these *RUNX* family members bind to the same nucleotide sequence (PuACCPuCA/TGPyGGTPy), each member has distinct tissue-specific roles ([@ref4]). All are deregulated in one way or another in human diseases, indicating they are intimately involved in the pathogenesis of human disease. This special issue describes the roles of *RUNX* proteins in developmental processes and tumorigenesis.

The regulatory function of *RUNX1* in hematopoiesis was first revealed when Runx1 was disrupted in mice ([@ref13]). *RUNX1* gene disruptions caused by chromosomal translocations and mutations are frequently detected in hematological diseases, such as acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), and myelodysplastic syndrome (MDS) ([@ref1]), indicating that *RUNX1* is intimately involved in hematopoiesis and hematopoietic lineage specification and its functional dysregulation is associated with leukemia. More recent studies show that *RUNX1* is also associated with various solid tumors.

The regulatory function of *RUNX2* in osteogenesis was first revealed when Runx2 was disrupted in mice ([@ref5]; [@ref14]). Based on these studies, further work showed that human autosomal dominant bone disease cleidocranial dysplasia (CCD) is caused by *RUNX2* haploinsufficiency ([@ref6]; [@ref12]; [@ref14]), establishing Runx2 as a master regulator of osteogenesis. Overexpression of *RUNX2* occurs in various solid tumors including osteosarcoma, lymphoma, and breast cancer, indicating that functional dysregulation of *RUNX2* is associated with tumorigenesis ([@ref2]; [@ref3]; [@ref15]).

Runx3 knockout mice, the result of a collaboration between my laboratory and that of Yoshiaki Ito ([@ref11]), cancer cell lines, and surgically dissected cancer tissues revealed that loss of *RUNX3* expression occurs in, and is causally related to, gastric cancer ([@ref11]). *RUNX3* inactivation in gastric cancer is the combined result of its hemizygous deletion and silencing by DNA hypermethylation ([@ref11]). Silencing of *RUNX3* by DNA hypermethylation was also observed in various other cancers, suggesting that *RUNX3* functions as a tumor suppressor ([@ref4]). Subsequent studies revealed that *RUNX3* plays key roles in suppressing not only gastric cancer but also lung cancer ([@ref10]). *RUNX3* also functions as an oncogene is some cancers. For example, *RUNX3* is overexpressed in head and neck cancer, squamous cell carcinoma (SCC), epithelial ovarian cancer, and basal cell carcinoma ([@ref7]; [@ref16]; [@ref17]). In pancreatic cancer, *RUNX3* functions as a tumor suppressor at the early stage and as an oncogene at the late stage of tumor progression ([@ref18]). These opposing roles of *RUNX3* can be reconciled by the recent observation that *RUNX3* is important for context-dependent cell fate decisions at the G1 restriction point, i.e., it determines whether cells progress through the cell cycle or enter apoptosis ([@ref8]). Therefore, *RUNX3* overexpression has the potential to disturb restriction point regulation and cause unprogrammed cell proliferation in some tissues.

*RUNX* family members have both tumor suppressive and oncogenic activity. What makes *RUNX* a tumor suppressor or an oncogene? This question can only be answered after we know more about how cancers develop and how *RUNX* genes determine cell fate, which is critical for regulating developmental processes in diverse tissues. In this regard, it is worth mentioning that restriction point regulation, which is critical in deciding whether cells proliferate, differentiate and undergo apoptosis, is disrupted in nearly all cancer cells. Recently, all three *RUNX* family members were shown to be involved in restriction point regulation ([@ref8]; [@ref9]). It is worth emphasizing that *RUNX* family members bind to the same nucleotide sequence. Therefore, the results of all these studies suggest that the diverse roles of *RUNX* family members can be explained, at least partly, by their participation in a common cell fate decision mechanism that makes cell type-specific and context-dependent decisions.
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